222
M. Sova et al. / Bioorganic Chemistry 37 (2009) 217–222
[13] G. Auger, J. van Heijenoort, D. Blanot, C. Deprun, J. Prakt. Chem. 337 (1995)
351–357.
[14] M.E. Tanner, S. Vaganay, J. van Heijenoort, D. Blanot, J. Org. Chem. 61 (1996)
1756–1760.
phosphate moiety of docked inhibitor 7a forms interactions with
the same amino acids (Thr157, Thr158, Ser184 and Arg192) as
the
a-carboxyl group of D-Glu of the co-crystallized product.
[15] L.D. Gegnas, S.T. Waddell, R.M. Chabin, S. Reddy, K.K. Wong, Bioorg. Med.
Chem. Lett. 8 (1998) 1643–1648.
Although HEA derivatives were designed as potential tetrahedral
transition-state analogue inhibitors, this docking study and the
micromolar affinities of our compounds suggest that they are not
analogues of the high-energy intermediate, which should have
nanomolar affinities and should display different types of interac-
tions, but most probably classical inhibitors interacting with the
binding site of the UDP-MurNAc-dipeptide substrate.
[16] S. Gobec, U. Urleb, G. Auger, D. Blanot, Pharmazie 56 (2001) 295–297.
[17] K. Štrancar, D. Blanot, S. Gobec, Bioorg. Med. Chem. Lett. 16 (2006) 343–348.
[18] M. Kotnik, J. Humljan, C. Contreras-Martel, M. Oblak, K. Kristan, M. Hervé, D.
Blanot, U. Urleb, S. Gobec, A. Dessen, T. Šolmajer, J. Mol. Biol. 370 (2007) 107–
115.
[19] J. Humljan, M. Kotnik, C. Contreras-Martel, D. Blanot, U. Urleb, A. Dessen, T.
Šolmajer, S. Gobec, J. Med. Chem. 51 (2008) 7486–7494.
[20] J. Humljan, M. Kotnik, A. Boniface, T. Šolmajer, U. Urleb, D. Blanot, S. Gobec,
Tetrahedron 62 (2006) 10980–10988.
5. Conclusions
[21] K. Štrancar, A. Boniface, D. Blanot, S. Gobec, Arch. Pharm. Chem. Life Sci. 340
(2007) 127–134.
[22] B. Zeng, K.K. Wong, D.L. Pompliano, S. Reddy, M.E. Tanner, J. Org. Chem. 63
(1998) 10081–10086.
[23] J. Miller, S.M. Hammond, D. Anderluzzi, T.D.H. Bugg, J. Chem. Soc. Perkin Trans.
(1998) 131–142.
In summary, we have synthesized a series of HEA derivatives as
potential inhibitors of Mur ligases. We have shown that only phos-
phorylated HEA derivatives are inhibitors. The most interesting of
them inhibit the activities of MurC, MurE and MurF at micromolar
concentrations, therefore are multiple inhibitors of Mur ligases.
The most potent inhibitor is 1-(4-methoxyphenylsulfonamido)-3-
morpholinopropan-2-yl diphenyl phosphate (7a), which is one of
[24] R.A.Wiley, D.H. Rich, Med. Res. Rev. 13 (1993) 327–384.
[25] E.K. Kick, J.A. Ellman, J. Med. Chem. 38 (1995) 1427–1430.
[26] P.L. Beaulieu, D. Wernic, J. Org. Chem. 61 (1996) 3635–3645.
[27] A. Datta, G. Veeresa, J. Org. Chem. 65 (2000) 7609–7611.
[28] D. Leung, G. Abbenante, D.P. Fairlie, J. Med. Chem. 43 (2000) 305–341.
[29] G. Abbenante, D.P. Fairlie, Med. Chem. 1 (2005) 71–104.
[30] A.K. Ghosh, G. Bilcer, G. Schiltz, Synthesis 15 (2001) 2203–2229.
[31] C.E. Lee, E.K. Kick, J.A. Ellman, J. Am. Chem. Soc. 120 (1998) 9735–9747.
[32] E.M. Gordon, J.D. Godfrey, J. Pluscec, D. Von Langen, S. Natarajan, Biochem.
Biophys. Res. Commun. 126 (1985) 419–426.
the best inhibitor of MurE so far with an IC50 value of 6 lM. As these
inhibitorscontainaverypolarphosphategroupsattachedtotheHEA
moiety, we do not expect them to have good antibacterial activity.
However, they do represent important hit compounds and promis-
ing starting points for further structural optimization and develop-
ment of multipleinhibitors of Mur ligases with antibacterial activity.
[33] D. Muthas, D. Noeteberg, Y.A. Sabnis, E. Hamelink, L. Vrang, B. Samuelsson, A.
Karlen, A. Hallberg, Bioorg. Med. Chem. 13 (2005) 5371–5390.
[34] D. Nöteberg, E. Hamelink, J. Hultén, M. Wahlgren, L. Vrang, B. Samuelsson, A.
Hallberg, J. Med. Chem. 46 (2003) 734–746.
[35] N. Ostermann, J. Eder, U. Eidhoff, F. Zink, U. Hassiepen, S. Worpenberg, J.
Maibaum, O. Simic, U. Hommel, B. Gerhartz, J. Mol. Biol. 355 (2006) 249–261.
[36] L. Rizzi, S. Romeo, Lett. Drug Des. Discov. 2 (2005) 109–112.
[37] H. Tamamura, T. Kato, A. Otaka, N. Fujii, Org. Biol. Chem. 1 (2001) 2468–2473.
[38] P. Beswick, N. Charrier, B. Clarke, E. Demont, C. Dingwall, R. Dunsdon, A. Faller,
R. Gleave, J. Hawkins, I. Hussain, C.N. Johnson, D. MacPherson, G. Maile, R.
Matico, P. Milner, J. Mosley, A. Naylor, A. O’Brien, S. Redshaw, D. Riddell, P.
Rowland, J. Skidmore, V. Soleil, K.J. Smitha, S. Stanway, G. Stemp, A. Stuart, S.
Sweitzer, P. Theobald, D. Vesey, D.S. Walter, J. Ward, G. Wayne, Bioorg. Med.
Chem. Lett. 18 (2008) 1022–1026.
Acknowledgments
This work was supported by the European Union FP6 Integrated
ProjectEUR-INTAFAR(ProjectNo. LSHM-CT-2004-512138), theCen-
tre National de la Recherche Scientifique (PICS 3729), the Franco-
Slovene Proteus programme (No. 14007PH) and the Ministry of
Higher Education, Science and Technology of the Republic of Slove-
nia. The authors thank Dr. Chris Berrie for critical reading of the
manuscript.
[39] A.K. Ghosh, N. Kumaragurubaran, L. Hong, S. Kulkarni, X. Xu, H.B. Miller, D.S.
Reddy, V. Weerasena, R. Turner, W. Chang, G. Koelsch, J. Tang, Bioorg. Med.
Chem. Lett. 18 (2008) 1031–1036.
ˇ
ˇ
[40] M. Sova, G. Cadez, S. Turk, V. Majce, S. Polanc, S. Batson, A.J. Lloyd, D.I. Roper,
C.W.G. Fishwick, S. Gobec, Bioorg. Med. Chem. Lett. 19 (2009) 1376–1379.
[41] D. Liger, A. Masson, D. Blanot, J. van Heijenoort, C. Parquet, Eur. J. Biochem. 230
(1995) 80–87.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
[42] G. Auger, L. Martin, J. Bertrand, P. Ferrari, E. Fanchon, S. Vaganay, Y.
Pétillot, J. van Heijenoort, D. Blanot, O. Dideberg, Protein Expr. Purif. 13
(1998) 23–29.
[43] A. Boniface, Etude des relations structure-activité au sein de la famille des Mur
synthétases, enzymes de la voie de biosynthèse du peptidoglycane. Doctoral
Thesis, University of Paris-Sud, 2007.
[44] S. Dementin, A. Bouhss, G. Auger, C. Parquet, D. Mengin-Lecreulx, O. Dideberg,
J. van Heijenoort, D. Blanot, Eur. J. Biochem. 268 (2001) 5800–5807.
[45] P.A. Lanzetta, L.J. Alvarez, P.S. Reinach, O. Candia, Anal. Biochem. 100 (1979)
95–97.
References
[1] M.N. Alekshun, S.B. Levy, Cell 128 (2007) 1037–1050.
[2] S.B. Levy, Adv. Drug Deliv. Rev. 57 (2005) 1446–1450.
[3] S.B. Levy, B. Marshall, Nat. Med. 10 (2004) S122–S128.
[4] D.M. Livermore, Clin. Infect. Dis. 36 (2003) S11–S23.
[5] H. Labischinski, H. Maidhof, Bacterial peptidoglycan: overview and evolving
concepts, in: J.M. Ghuysen, R. Hakenbeck (Eds.), Bacterial Cell Wall, Elsevier
Science, Amsterdam, 1994, pp. 23–38.
[46] M. Rarey, B. Kramer, T. Lengauer, G. Klebe, J. Mol. Biol. 261 (1996) 470–489.
ˇ
ˇ
[47] M. Sova, A. Babic, S. Pecar, S. Gobec, Tetrahedron 63 (2007) 141–147.
[48] S.L. McGovern, B.K. Shoichet, J. Med. Chem. 43 (2003) 1478–1483.
[49] M. Abo-Ghalia, M. Flegel, D. Blanot, J. van Heijenoort, Int. J. Peptide Protein Res.
32 (1988) 208–222.
ˇ
[6] H. Barreteau, A. Kovac, A. Boniface, M. Sova, S. Gobec, D. Blanot, FEMS
Microbiol. Rev. 32 (2008) 168–207.
[7] P. Courvalin, J. Davies, Curr. Opin. Microbiol. 6 (2003) 425–426.
[8] A.E. Zoeiby, F. Sanschagrin, R.C. Levesque, Mol. Microbiol. 47 (2003) 1–12.
[9] W. Vollmer, D. Blanot, M.A. De Pedro, FEMS Microbiol. Rev. 32 (2008) 149–167.
[50] P. Le Roux, G. Auger, J. van Heijenoort, D. Blanot, Eur. J. Med. Chem. 27 (1992)
899–907.
[51] T.S. Mansur, C.E. Caufield, B. Rasmussen, R. Chopra, G. Krishnamurthy, K.M.
Morris, K. Svenson, J. Bard, C. Smeltzer, S. Naughton, S. Antane, Y. Yang, A.
Severin, D. Quagliato, P.J. Petersen, G. Singh, Chem. Med. Chem. 2 (2007) 1414–
1417.
ˇ
ˇ
[10] M. Kotnik, P. Štefanic Anderluh, A. Prezelj, Curr. Pharm. Des. 22 (2007) 2283–
2309.
[11] S. Marmor, C.P. Petersen, F. Reck, W. Yang, N. Gao, S.L. Fisher, Biochemistry 40
(2001) 12207–12214.
[12] F. Reck, S. Marmor, S. Fisher, M.A. Wuonola, Bioorg. Med. Chem. Lett. 11 (2001)
1451–1454.
[52] E. Gordon, B. Flouret, L. Chantalat, J. van Heijenoort, D. Mengin-Lecreulx, O.
Dideberg, J. Biol. Chem. 276 (2001) 10999–11006.